About DDDPH: A Working Guide to the Drug Development and Public Health Data Layer

DDDPH stands for Drug Development and Public Health, and the term covers two connected things: a reference data model and the integration layer that sits between clinical trial systems and population health records. Teams adopt it because they keep hitting the same wall. A single Phase III study can generate 3 to 5 million data points across 400 sites, while the regulator and payer evaluating the resulting therapy work from registries, claims feeds, and discharge summaries that never shared a common key. DDDPH is an attempt to make those two worlds speak the same language without forcing either side to rip out its existing stack.

The Case for a Shared Vocabulary

Clinical research runs on CDISC standards — SDTM 1.8 for tabulation, ADaM for analysis — plus MedDRA 27.1 for adverse events and WHO Drug Dictionary Enhanced for coding concomitant medications. Public health runs on something else entirely: ICD-10-CM, LOINC 2.77, SNOMED CT, and HL7 v2.5 messages that vary by hospital. When a safety team wants to know how many people in a 2.4 million-member claims database match the inclusion criteria of a trial, someone ends up building a one-off crosswalk in Excel. DDDPH replaces that recurring project with a mapped layer, so the same patient cohort can be described once and queried from both sides.

What It Looks Like in Practice

A mid-sized oncology sponsor running a study across 62 sites in the US, Poland, and Vietnam typically stores data in three systems: an EDC platform, a lab portal, and a safety database. Under a DDDPH implementation, those feeds land in a common structure keyed on a pseudonymized patient identifier, with oncology-specific extensions for RECIST 1.1 response assessments and CTCAE v5.0 grading. The practical effect is unglamorous but measurable. Source data verification time per patient drops from roughly 18 hours to 6, because monitors query a single reconciled view instead of three partially overlapping ones. Query resolution rates fall by 25 to 35 percent within two study cycles.

The Numbers That Justify the Effort

Bringing one drug to market costs a median of about 2.3 billion dollars and takes 10 to 12 years, and data management and site monitoring account for a meaningful slice of that. Analysts who model DDDPH deployments commonly cite 12 to 18 percent savings on the data management line, which for a 40 million dollar Phase II program is between 4.8 and 7.2 million dollars. The savings do not come from cutting headcount. They come from removing rework: duplicate entry, manual coding reconciliation, and the retrospective mapping exercise that sponsors pay for every time a health authority asks a question the original dataset cannot answer directly.

Interoperability Is the Hard Part

FHIR R4 is the obvious bridge, and it is genuinely useful for exchanging observations, medication statements, and diagnostic reports. It is also incomplete for trial work. FHIR has no native representation for a protocol deviation, a randomization schedule, or a blinded endpoint adjudication. DDDPH handles this by treating FHIR as a transport layer rather than a data model, keeping trial-specific concepts in extension profiles while population health concepts map to OMOP CDM v5.4 tables. That split sounds academic until you try to reconcile a serious adverse event reported in an EDC system with a hospitalization visible in a national registry three weeks later. The extension profile is what makes that match possible without manual review.

Governance and Consent

No data layer survives contact with a privacy officer unless consent and legal basis are handled explicitly. DDDPH implementations typically separate three permission tiers: identifiable data held at the site, pseudonymized data held by the sponsor, and aggregated or de-identified data released for secondary research. GDPR Article 9, HIPAA, Singapore's PDPA, and Vietnam's Decree 13/2023/ND-CP all impose different constraints on cross-border transfer, so the layer needs per-jurisdiction rules rather than a global switch. Audit trails must satisfy 21 CFR Part 11 and ICH E6(R3) expectations, which means every query, transformation, and export is logged with a timestamp and user identity.

Common Misconceptions

Four claims about DDDPH show up often and are wrong. It is not an EDC replacement — most teams keep their existing system and add DDDPH downstream. It is not an AI product; the machine learning components, where they exist, handle coding suggestions and anomaly flags, and they sit on top of curated data rather than replacing it. It is not a single vendor's product, despite how some sales decks present it. And it does not shorten regulatory review. What it shortens is the time between a question being asked and a defensible answer being produced.

How Teams Start

A pilot usually runs four to six weeks and covers two therapeutic areas. The steps are consistent: pick 40 to 60 priority fields, map them against SDTM and OMOP simultaneously, run the new layer in shadow mode alongside the current process for one study, then compare query volumes and reconciliation hours. If shadow mode does not show at least a 20 percent reduction in reconciliation effort, the mapping is too coarse and needs another pass before rollout.

Where It Still Falls Short

Roughly 60 percent of hospital data remains unstructured clinical notes, and DDDPH's handling of free text is improving but not solved. Pediatric dosing data is sparse, rare disease studies rarely have enough patients to validate cohort-matching rules, and imaging endpoints still travel outside the layer in most deployments. None of these gaps are fatal. They do mean the layer works best where structured data already dominates: oncology, cardiology, diabetes, and infectious disease surveillance.

For sponsors and health agencies weighing whether to build this capability, the honest answer is that DDDPH rewards teams with disciplined data governance and punishes teams that treat mapping as a one-time project. The organizations getting the most out of it treat the mapping dictionary as a living asset, reviewed quarterly, versioned like code, and owned by someone whose job depends on it staying accurate.